Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Analysis & Investment Frameworks
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) stock analysis on Invetso. Review Hemab Therapeutics Holdings, Inc. Common Stock’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Hemab Therapeutics Holdings, Inc. Common Stock Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Hemab Therapeutics Holdings, Inc. Common Stock Key Financial Metrics
- Market Cap: $2.13B
- Revenue: $N/A
- ROE: -36.64%
- ROIC: -10.91%
- Dividend Yield: N/A
About Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.